Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was down 0.2% on Thursday . The company traded as low as $791.50 and last ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

With the festival season of Christmas and New Year's around, tech billionaire Elon Musk shared a photo on his social media ...

Tirzepatide is the active ingredient in the FDA-approved versions of the drug, Mounjaro and Zepbound, which are made by the ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Tesla chief Elon Musk dubbed himself “Ozempic Santa” in an X post on Christmas Day, marking the tech billionaire’s latest ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...